Ascend Therapeutics US, LLC
$74.6K 282 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Lightbody Medical Technologies Inc
Lightbody Medical Technologies Inc reported $74,256.62 across General Payments, Research, and Ownership to 678 physicians and teaching hospitals across 678 transactions.
- $74.3K
- All-tracks total
- 678
- Transactions
- 678
- Recipients
- +$67.9K
- General Payments vs PY2023
Lightbody Medical Technologies Inc reported $74,256.62 across all CMS Open Payments tracks (General + Research + Ownership) to 678 physicians and teaching hospitals in Program Year 2024 - ranking #1259 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $74,256.62, averaging $109.52 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer lightbody-medical-technologies-inc Lightbody Medical Technologies Inc
$74.3K · #1259/1,925 · 0.0% industry · PY2024
- TOT $74.3K
- RANK #1259
- SHARE 0.0%
- TXN 678
- RCP 678
- CAT 2
- GEN $74.3K
- ΔGEN +$67.9K
- TOP1 1.9%
- PY 2024
Volume peers
Nearest volume peer: Ascend Therapeutics US, LLC ($74.6K)
Lightbody Medical Technologies Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Lightbody Medical Technologies Inc's CMS-reported General Payments increased by $67.9K (+1061.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: LIGHTBODY MEDICAL TECHNOLOGIES INCPY2024: Lightbody Medical Technologies Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $6,395.23
- PY2024
- $74,256.62
What the Data Shows for Lightbody Medical Technologies Inc
$74,256.62: that is what Lightbody Medical Technologies Inc reported in payments to 678 physicians and teaching hospitals during Program Year 2024, spread across 678 transactions ($109.52 per transaction, $109.52 per recipient). The company sits at rank #1259 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 2 general-payment categories charted below, "Food and Beverage" is the largest at $41.2K across 594 transactions, 55.5% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, Lightbody Medical Technologies Inc's largest category was "Food and Beverage" at $41.2K - 55.5% of General Payments.
How Lightbody Medical Technologies Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $41.2K | 594 | 55.5% |
| Travel and Lodging | $33.1K | 84 | 44.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $6,580.32 (8.9%) of $74,256.62 in this company's General Payments records across 422 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Lightbody Medical Technologies Inc
The five named recipients with the highest reported General Payments from this company
- 1
Joseph Weistroffer
$1,400.56 across 12 reported transactions
- 2
Sarah Harangody
$1,370.65 across 4 reported transactions
- 3
Gregory Primus
$1,289.52 across 3 reported transactions
- 4
Bryant Castelein
$1,267.46 across 6 reported transactions
- 5
Thomas Mcnally
$1,252.13 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Lightbody Medical Technologies Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Lightbody Medical Technologies Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Lightbody Medical Technologies Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Aspira Women's Health Inc
$74.7K 3,127 recipients
Compare payment profiles
Clariance SAS
$73.8K 57 recipients
Compare payment profiles
Evolution Surgical, Inc
$74.8K 667 recipients
Compare payment profiles
Mevion_Medical_Systems_Inc
$73.7K 71 recipients
Compare payment profiles
Omniscient Neurotechnology America Ltd
$73.2K 72 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.